FindTrial
Sign In

Effects of Rocuronium on ischemia damage in skeletal muscle

Effects of Rocuronium on ischemia damage in skeletal muscle

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800019221
Enrollment
Unknown
Registered
2018-10-31
Start date
2018-11-10
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total knee arthroplasty

Interventions

Three Groups:dosage of rocuronium

Sponsors

Affiliated Hospital of Xuzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ASA I-II, aged from 50 to 80 years old, weight from 40 to 80kg, people who require knee replacement.

Exclusion criteria

Exclusion criteria: People with infectious diseases; For those who are using cholinergic or adrenal drugs; Fat person; People with diabetes; Severe anemia; Congestive heart failure and coagulation dysfunction; Severe damage to kidney and liver; Those with metabolic diseases or respiratory diseases; Those who are allergic to the anesthetic. Tourniquet inflation time estimated at >150 min.

Design outcomes

Primary

MeasureTime frame
muscle fibre vitality;—

Secondary

MeasureTime frame
VAS assessment after operation;—

Countries

China

Contacts

Public ContactZhang Yueying

Affiliated Hospital of Xuzhou Medical University

zyy0218@126.com+86 13815310789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 17, 2026